Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes
NCT07254572 on ClinicalTrials.gov · last registry update 2025-11-28
An unusually large phase 4: 300 participants, more than double the 75 typical for the stage. Due to report 1 August 2029. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is approved in the US, but not for prediabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- RECRUITING
- Phase
- P4
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- National Institute of Cardiology, Warsaw, Poland
- Sponsor type
- Other
- Enrollment
- 300
- Started
- 2025-07-10
- Primary completion
- 2029-08-01 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Evaluation of the effect of GLP-1 analogue treatment on coronary artery disease progression AND Evaluation of the effect of flozin treatment on the progression of coronary artery disease (CO-PRIMARY ENDPOINTS)
Conditions studied
Coronary Artery Disease · PreDiabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.